Tap the pharmaceutical "potential unit" and cooperate in research and development into the core link of the pipeline widening of pharmaceutical companies

Compared with generic drugs, innovative drug research and development "high investment, long cycle, high return uncertainty" characteristics are distinct, a new drug from the active molecule screening to the market put into production, the average need for 10 to 15 years, at least 1 billion U.S. dollars, therefore, in the past a long time, China's pharmaceutical enterprises to produce generic drugs mainly, research and development innovation capacity is relatively weak.
, however, with the deepening of new medical reform, the pharmaceutical industry has gradually transitioned from imitation to innovation, and the golden age of innovative medicine has arrived.
It is learned that in the high cost of drug research and development, compared with the cost of a large number of human, material and financial resources of independent research and development model, more and more domestic and foreign pharmaceutical companies choose the transfer of drug results or transfer of cooperative research and development model, so that the two sides to achieve greater benefits with less risk.
such as qingdao Baiyang Pharmaceutical Co., Ltd. and Shanghai Alice Pharmaceutical Technology Co., Ltd. recently signed a strategic cooperation agreement to jointly expand the innovative drug Blue Sea.
this time, Baiyang Pharmaceuticals and Alice Pharmaceuticals are in-depth strategic cooperation, mainly around the commercialization of innovative drugs and capital cooperation.
In the commercial cooperation, Baiyang will play a deep-farming industry for many years of resource advantages, in the patent drug market, the national DTP pharmacy channel services, hospital access and supply chain services for Alice Pharmaceuticals to provide the overall solution, to help Alice Pharmaceuticals innovative products to achieve end-market coverage, fast access to the application scenario.
capital cooperation, the two sides will discuss in-depth cooperation in capital areas such as equity and investment, and build various forms of capital cooperation, with a view to realizing greater value in the pharmaceutical market.
, on October 15th, Hunan Zhongzhu Whole Peptide Biopharmaceutical Co., Ltd. announced a new drug development cooperation with Lizhu Pharmaceutical Group Co., Ltd., which will use ZSen, which is built using its Peptide Information Compression Technology (PICT). ithFive peptide technology platform and new drug screening platform, in lizhu medicine focus on digestion, anti-tumor and other fields found a new peptide pilot compounds and follow-up development together, Lizhu pharmaceutical use of its own advanced long-lasting micro-ball technology to commercialize products.
In recent years, the state has continuously introduced policies to encourage drug innovation, accelerated the implementation of a number of policies, such as the review and approval system, the drug market license holder system, innovative drugs into the medical insurance drug catalog and other policies, China's innovative drug policy environment has been fundamentally improved, innovative drug research and development into a period of rapid development.
At the same time, with the promotion of the national volume procurement policy, many enterprises began to lay out new drug research and development innovation, with continuous research and development innovation ability, innovative pharmaceutical products listed enterprises, its corporate value is also being highlighted.
strong joint, can win-win situation.
to promote the development of innovative drugs in China, so that valuable new drugs, good drugs to benefit more patients.
more and more enterprises began to carry out strong union.
In addition, for start-ups or small and medium-sized innovative pharmaceutical companies with research and development capabilities, a number of clinically-staged products can be cashed out in a "License out" manner, while for pharmaceutical companies with strong commercial capabilities, the "License in" model can quickly enrich their own research and development pipeline, cut into new business areas.
data show that in recent years, most of the approved new drugs were initially developed by smaller biopharmaceutical companies, according to the pharmaceutical Rubik's Cube NextPharma database included in the domestic pharmaceutical project "License in" transaction cases, as of April 2020, in the last five years, a total of 200 innovative drug projects, involving 186 transactions.
with the rapid development of the domestic economy, under the threat of capital, pharmaceutical companies through the "License in" to obtain new varieties has become a trend.
the risk of pharmaceutical research and development is very high, the cooperative research and development model has greatly improved the level of research and development, improve the clinical success rate, the industry predicts that "License in" will become the core link of pharmaceutical companies to broaden the research and development pipeline.